PART I Overview Ovid is a biopharmaceutical company that is dedicated to developing small molecule medicines for brain disorders with significant unmet need. These potential medicines targeting the central nervous system (CNS) are designed to potentially halt the course of brain disease by quelling neuronal hyperexcitation and alleviating the most impactful patient symptoms. We seek to address fundamental biological targets in the brain that are implicated in neuronal hyperexcitability, such as ...
Q2 FY2026 — expected 2026-09-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-18 | 2025-12-31 | 0001628280-26-019438 | EDGAR | 69K words |
| 2025-03-11 | 2024-12-31 | 0001628280-25-011844 | EDGAR | — |
| 2024-03-08 | 2023-12-31 | 0001628280-24-009809 | EDGAR | — |
| 2023-03-13 | 2022-12-31 | 0001628280-23-007648 | EDGAR | — |
| 2022-03-15 | 2021-12-31 | 0000950170-22-003668 | EDGAR | — |
| 2021-03-15 | 2020-12-31 | 0001564590-21-013016 | EDGAR | — |
| 2020-03-11 | 2019-12-31 | 0001564590-20-010108 | EDGAR | — |
| 2019-03-07 | 2018-12-31 | 0001564590-19-006804 | EDGAR | — |
| 2018-03-29 | 2017-12-31 | 0001564590-18-007152 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001636651-25-000012 | EDGAR | 51K words |
| 2025-08-13 | 2025-06-30 | 0001628280-25-040008 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001628280-25-024913 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001628280-24-046868 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001628280-24-036860 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001628280-24-023067 | EDGAR | — |
| 2023-11-03 | 2023-09-30 | 0001628280-23-036564 | EDGAR | — |
| 2023-08-04 | 2023-06-30 | 0001628280-23-027430 | EDGAR | — |
| 2023-05-05 | 2023-03-31 | 0001628280-23-016013 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001628280-22-028772 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001628280-22-021759 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0000950170-22-008739 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-18 | 0001628280-26-019045 | EDGAR | 20K words |
| 2025-12-18 | 0001193125-25-323798 | EDGAR | — |
| 2025-12-11 | 0001636651-25-000017 | EDGAR | — |
| 2025-11-12 | 0001636651-25-000011 | EDGAR | — |
| 2025-10-03 | 0001193125-25-230409 | EDGAR | — |
| 2025-09-16 | 0001193125-25-204308 | EDGAR | — |
| 2025-08-13 | 0001628280-25-040007 | EDGAR | — |
| 2025-07-10 | 0001628280-25-034733 | EDGAR | — |
| 2025-06-25 | 0001628280-25-032959 | EDGAR | — |
| 2025-05-13 | 0001628280-25-024911 | EDGAR | — |
201 total filings indexed. 170 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001636651 |
| Ticker | OVID |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.ovidrx.com |
| Listed | 2017-05-05 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report